Rapport Therapeutics, Inc. (RAPP) Investor Relations Documents

Rapport Therapeutics, Inc. (RAPP) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-08-04. Read in-app with summaries. First-party data.

Rapport Corporate Presentation, August 2026: Rapport Therapeutics is a clinical-stage neuroscience company developing precision medicines, with RAP-219 in Phase 3 for focal onset seizures.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseRapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
2026-08-04PresentationRapport Corporate Presentation, August 2026
2026-05-20Press releaseRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global H
2026-05-07Press releaseRapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2026-04-21Press releaseRapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seiz
2026-04-01Press releaseRapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 Ame
2026-06-06DocumentPDF Version
2026-03-10Press releaseRapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-09Press releaseRapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercializatio
2026-02-24Press releaseRapport Therapeutics to Participate in Upcoming Investor Conferences
2026-01-07Press releaseRapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and C

RAPP overview · RAPP earnings · RAPP financials · RAPP KPIs · RAPP documents · RAPP ownership · RAPP peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.